Patrick Chalbos

443 total citations
9 papers, 352 citations indexed

About

Patrick Chalbos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Patrick Chalbos has authored 9 papers receiving a total of 352 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Cancer Research. Recurrent topics in Patrick Chalbos's work include Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Patrick Chalbos is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Gastric Cancer Management and Outcomes (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Patrick Chalbos collaborates with scholars based in France. Patrick Chalbos's co-authors include Marc Ychou, Franck Molina, Corinne Bareil, Pierre Martineau, Andrew Kramar, Virginie Copois, Nicolas Salvetat, Frédéric Bibeau, Caroline Fraslon and V. Granci and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Journal of Biotechnology.

In The Last Decade

Patrick Chalbos

9 papers receiving 344 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick Chalbos France 5 210 128 73 54 49 9 352
Zhu‐Ting Tong China 9 299 1.4× 96 0.8× 148 2.0× 45 0.8× 32 0.7× 10 443
Wenjun Bie United States 12 406 1.9× 230 1.8× 66 0.9× 44 0.8× 35 0.7× 18 527
Steve Busch United States 8 190 0.9× 68 0.5× 46 0.6× 60 1.1× 16 0.3× 10 354
Fernando Martínez‐Arribas Spain 11 258 1.2× 119 0.9× 105 1.4× 29 0.5× 31 0.6× 16 368
Kristen S. Hill United States 11 228 1.1× 110 0.9× 68 0.9× 30 0.6× 23 0.5× 24 361
Nima Niknejad Canada 14 273 1.3× 90 0.7× 115 1.6× 58 1.1× 32 0.7× 18 431
Shigeru Sugaya Japan 12 272 1.3× 80 0.6× 72 1.0× 20 0.4× 25 0.5× 33 403
Mianen Sun United States 8 279 1.3× 108 0.8× 106 1.5× 46 0.9× 13 0.3× 17 357

Countries citing papers authored by Patrick Chalbos

Since Specialization
Citations

This map shows the geographic impact of Patrick Chalbos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Chalbos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Chalbos more than expected).

Fields of papers citing papers by Patrick Chalbos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Chalbos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Chalbos. The network helps show where Patrick Chalbos may publish in the future.

Co-authorship network of co-authors of Patrick Chalbos

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Chalbos. A scholar is included among the top collaborators of Patrick Chalbos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Chalbos. Patrick Chalbos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2024). Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemotherapy and Pharmacology. 94(3). 443–452. 1 indexed citations
2.
3.
Adenis, Antoine, François Ghiringhelli, Thibault Mazard, et al.. (2022). Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.. Journal of Clinical Oncology. 40(16_suppl). 3561–3561. 1 indexed citations
4.
Adenis, Antoine, Thibault Mazard, Julien Fraisse, et al.. (2021). FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer. BMC Cancer. 21(1). 564–564. 4 indexed citations
5.
6.
Rio, Maguy Del, Franck Molina, Caroline Mollévi, et al.. (2007). Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan. Journal of Clinical Oncology. 25(7). 773–780. 158 indexed citations
7.
Duffour, Jacqueline, Sophie Gourgou, Françoise Desseigne, et al.. (2006). Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 60(3). 383–389. 16 indexed citations
8.
Copois, Virginie, Frédéric Bibeau, Caroline Mollévi, et al.. (2006). Impact of RNA degradation on gene expression profiles: Assessment of different methods to reliably determine RNA quality. Journal of Biotechnology. 127(4). 549–559. 151 indexed citations
9.
Ychou, Marc, Sophie Gourgou, Françoise Desseigne, et al.. (2004). Multicenter phase II study using increasing dose of irinotecan (CPT11) combined with simplified LV5FU regimen in metastatic colorectal cancer (MCRC). Journal of Clinical Oncology. 22(14_suppl). 3601–3601. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhu‐Ting Tong Breakdown of academic impact, for papers by Wenjun Bie Breakdown of academic impact, for papers by Steve Busch Breakdown of academic impact, for papers by Fernando Martínez‐Arribas Breakdown of academic impact, for papers by Kristen S. Hill Breakdown of academic impact, for papers by Nima Niknejad Breakdown of academic impact, for papers by Shigeru Sugaya Breakdown of academic impact, for papers by Mianen Sun
Rankless by CCL
2026